Infectious Disease Point-of-care (POC) Diagnostics Market Size, Share & COVID-19 Impact Analysis, By Technique (Lateral Flow Immunoassay, Agglutination Test and Others), By Disease (HIV, Hepatitis B Virus, Pneumonia/Streptococcus Associated Infections, RSV, Influenza, Clostridium Difficile Infections, Hepatitis C Virus, Methicillin-Resistant Staphylococcus Aureus, Tuberculosis, and Others), By Disease, COVID-19 Point-of-care (POC) Diagnostics, By End User (Hospital Bedside, Physicians Office Lab, Urgent Care & Retail Clinics and Others), and Regional Forecast, 2023-2030

Last Updated: January 27, 2025 | Format: PDF | Report ID: FBI104307

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2019-2030
Base Year	2022
Estimated Year	2023
Forecast Period	2023-2030
Historical Period	2019-2021
Unit	Value (USD Billion)
Growth Rate	CAGR of -2.8% from 2023-2030
Segmentation	By Technique Lateral Flow Immunoassay (LFIA) Agglutination Test Flow-through test/Immunoconcentration Assay Molecular Diagnostics Others
	By Disease HIV Hepatitis B Virus Pneumonia/Streptococcus Associated Infections Respiratory Syncytial Virus (RSV) Influenza Clostridium Difficile Infections (CDI) Hepatitis C Virus Methicillin-Resistant Staphylococcus Aureus (MRSA) Tuberculosis (TB) COVID-19 Others
	By End-User Hospital Bedside Physician's Office Lab Urgent Care & Retail Clinics Home & Self-testing Nursing Home Others
	By Geography North America (U.S. and Canada) Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe) Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific) Latin America (Brazil, Mexico, and Rest of Latin America) Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)